0000890821 false 0000890821 2022-09-20
2022-09-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of
1934
September 20, 2022
Date
of Report (Date of earliest event reported)
Enveric Biosciences, Inc.
(Exact
name of registrant as specified in its charter)
Delaware |
|
001-38286 |
|
95-4484725 |
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(I.R.S.
Employer
Identification
No.)
|
Enveric Biosciences, Inc.
4851 Tamiami Trail N,
Suite 200
Naples,
FL
34103
(Address of principal executive offices) (Zip code)
Registrant’s
telephone number, including area code:
(239)
302-1707
N/A
(Former name or former address, if changed since last
report.)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425) |
|
|
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
|
|
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)) |
|
|
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common stock, par value $0.01 per share |
|
ENVB |
|
The Nasdaq Stock Market |
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405 of
this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
(§240.12b-2 of this chapter).
Emerging
growth company
☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Item
4.01 Changes in Registrant’s Certifying Accountant.
(a)
Dismissal of Independent Registered Public Accounting
Firm.
Based
on information provided by Friedman LLP (“Friedman”), the
independent registered public accounting firm of Enveric
Biosciences, Inc. (the “Company”), effective September 1, 2022,
Friedman combined with Marcum LLP (“Marcum”) and continued to
operate as an independent registered public accounting firm as a
wholly-owned subsidiary of Marcum. Friedman continued to serve as
the Company’s independent registered public accounting firm through
September 20, 2022. On September 20, 2022, Friedman was dismissed,
and Marcum was engaged to serve as the independent registered
public accounting firm of the Company for the fiscal year ending
December 31, 2022, effective immediately. The services previously
provided by Friedman will now be provided by Marcum.
The
report of Friedman on the Company’s consolidated financial
statements for the fiscal year ended December 31, 2021 did not
contain an adverse opinion or a disclaimer of opinion and were not
qualified or modified as to uncertainty, audit scope, or accounting
principles.
During
the fiscal year ended December 31, 2021, and through September 20,
2022, there were no disagreements, as defined in Item 304 of
Regulation S-K, with Friedman on any matter of accounting
principles or practices, financial statement disclosure, or
auditing scope or procedure, which disagreements, if not resolved
to the satisfaction of Friedman, would have caused Friedman to make
reference to the subject matter of the disagreements in connection
with its reports on the Company’s consolidated financial statements
for such period, and there were no “reportable events,” as defined
in Item 304(a)(1)(v) of Regulation S-K
In
its Management’s Report on Internal Control Over Financial
Reporting, as set forth in Item 4 “Controls and Procedures” of the
Company’s Quarterly Reports on Form 10-Q for the quarters ended
March 31, 2022 and June 30, 2022, and Item 9A “Controls and
Procedures” of the Company’s Annual Report on Form 10-K for the
year ended December 31, 2021, the Company reported material
weaknesses in its internal controls over financial reporting, which
constitute reportable events (as defined in Item 304(a)(1)(v) of
Regulation S-K). The material weakness was due to the small size of
the Company, and the fact the Company does not maintain sufficient
segregation of duties to ensure the processing, review and
authorization of all transactions including non-routine
transactions. The Audit Committee discussed the subject matter of
the reportable events with Friedman and notwithstanding these
material weaknesses in internal control over financial reporting,
the Company has concluded that, based on its knowledge, the
consolidated financial statements, and other financial information
included in its Annual Reports on Form 10-K for the fiscal year
ended December 31, 2021 present fairly, in all material respects
the Company’s financial condition, results of operations and cash
flows for the periods presented in conformity with accounting
principles generally accepted in the United States.
We
provided Friedman with a copy of the above disclosure and requested
that Friedman furnish the Company with a letter addressed to the
Securities and Exchange Commission (the “SEC”) stating whether or
not it agrees with the statements made by the Company above. A copy
of Friedman’s letter will be filed with the SEC within ten business
days after the filing of this Current Report on Form
8-K.
(b)
Appointment of New Independent Registered Public Accounting
Firm.
On
September 20, 2022, the Company engaged Marcum as the Company’s
independent registered public accounting firm for the fiscal year
ending December 31, 2022, effective immediately. During the fiscal
years ended December 31, 2021 and December 31, 2020, and through
September 20, 2022, neither the Company nor anyone acting on its
behalf has consulted with Marcum regarding (i) the application of
accounting principles to any specified transaction, either
completed or proposed, or the type of audit opinion that might be
rendered on the Company’s consolidated financial statements and
neither a written report nor oral advice was provided to the
Company that Marcum concluded was an important factor considered by
the Company in reaching a decision as to any accounting, auditing,
or financial reporting issue, except pursuant to Marcum’s
engagement as the Company’s independent auditor prior to June 23,
2021 and as disclosed in the Current Report on Form 8-K/A filed on
June 29, 2021, or (ii) any matter that was either the subject of a
“disagreement,” as defined in Item 304(a)(1)(iv) of Regulation S-K,
or a “reportable event,” as defined in Item 304(a)(1)(v) of
Regulation S-K, except pursuant to Marcum’s engagement as the
Company’s independent auditor prior to June 23, 2021 and as
disclosed in the Current Report on Form 8-K/A filed on June 29,
2021.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Date:
September 23, 2022 |
ENVERIC
BIOSCIENCES, INC. |
|
|
|
By: |
/s/
Joseph Tucker |
|
|
Joseph
Tucker |
|
|
Chief
Executive Officer |
Ameri (NASDAQ:AMRH)
Historical Stock Chart
From Feb 2023 to Mar 2023
Ameri (NASDAQ:AMRH)
Historical Stock Chart
From Mar 2022 to Mar 2023